Colleen Kusy
Stock Analyst at Baird
(0.89)
# 4,648
Out of 4,648 analysts
35
Total ratings
25.93%
Success rate
-15.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $96 → $92 | $29.64 | +210.39% | 9 | Sep 23, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $1.86 | +61.73% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $10.33 | +64.57% | 4 | Aug 8, 2024 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $9 → $8 | $0.72 | +1,003.60% | 3 | Jul 1, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $17.74 | +108.57% | 3 | Jun 11, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | $32 | $27.63 | +15.82% | 1 | Jun 11, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $50 | $33.37 | +49.86% | 1 | May 2, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.40 | +165.96% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $88.84 | +18.20% | 1 | Feb 23, 2024 | |
| AGEN Agenus | Initiates: Outperform | $160 | $4.03 | +3,870.22% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $0.93 | +1,402.95% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $11.22 | +203.17% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $4.08 | +5,537.25% | 1 | Nov 2, 2021 |
Apellis Pharmaceuticals
Sep 23, 2024
Maintains: Outperform
Price Target: $96 → $92
Current: $29.64
Upside: +210.39%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.86
Upside: +61.73%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $10.33
Upside: +64.57%
Coherus BioSciences
Jul 1, 2024
Maintains: Outperform
Price Target: $9 → $8
Current: $0.72
Upside: +1,003.60%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $17.74
Upside: +108.57%
Enliven Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: $32
Current: $27.63
Upside: +15.82%
Spyre Therapeutics
May 2, 2024
Initiates: Outperform
Price Target: $50
Current: $33.37
Upside: +49.86%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.40
Upside: +165.96%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $88.84
Upside: +18.20%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $4.03
Upside: +3,870.22%
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.93
Upside: +1,402.95%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $11.22
Upside: +203.17%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.08
Upside: +5,537.25%